Prise en charge des hypertriglycéridémies et du risque de pancréatite [The management of hypertriglyceridemia and the risk of pancreatitis]
Fiche du document
4 mars 2020
- doi: 10.53738/REVMED.2020.16.684.0451
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.684.0451
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32134224
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D23403F835DB4
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
HypertriglyceremiaCiter ce document
V. Garelli et al., « Prise en charge des hypertriglycéridémies et du risque de pancréatite [The management of hypertriglyceridemia and the risk of pancreatitis] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.684.0451
Métriques
Partage / Export
Résumé
In the face of hypertriglyceridemia, the potential causes must be assessed to choose the best medical therapeutic option. In cases of secondary hypertriglyceridemia, physicians should use treatments targeting the pathophysiological mechanisms underlying the lipid disorder. Lifestyle interventions are the cornerstone of an effective treatment, to achieve controlled glycemia, blood pressure and weight loss. Only in cases where these measures are insufficient, fibrates can be trialed although their clinical benefit is controversial, with special caution when combined with statins (risk of rhabdomyolysis). Plasmapheresis or intravenous insulin therapy are only used in severe situations after a multidisciplinary decision process in the hospital setting. The clinical case presented here reminds us to assess hypertriglyceridemia in the face of any acute pancreatitis.